A biomarker and therapeutical target in immune thrombocytopenia: TNF receptor-associated factor 6
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Immune thrombocytopenia (ITP) is an acquired disease characterized by various pathogenetic mechanisms. We aimed to evaluate the value of TRAF6 as a biomarker of pathogenesis in ITP. Methods:85 newly diagnosed ITP patients and 85 controls were included. Results: In the patient group, mean TRAF6 level was 2348pg/ml and in the control group, TRAF6 level was 25.57pg/ml. In corticosteroid-responding patients, TRAF6 levels were lower than nonresponding patients. Discussion: TRAF6 levels were observed to be higher than healthy controls, which suggest a solid relation with ITP pathogenesis. The observation that in patients who present with high TRAF6 levels, there was a significant corticosteroid refractoriness and responsiveness.
Açıklama
Anahtar Kelimeler
Immune Thrombocytopenia, Immunity, TRAF6, Purpura, Pathophysiology, Autoantibodies
Kaynak
Biomarkers In Medicine
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
13
Sayı
1
